| 2021 | 2022 | 2023 | 2024 (projected) | |
| Total Stockholder Equity | 65.5M | 38.5M | 14.9M | 14.1M |
| Total Current Liabilities | 11.7M | 19.3M | 12.7M | 7.9M |
Reasons NuCana PLC (USA Stocks:NCNA) can excite investors
 | By Ellen Johnson | Macroaxis Story |
We offer trading recommendations for NuCana PLC, supplementing the latest expert consensus. Our advanced recommendation engine uses a multidimensional algorithm to assess the company's growth potential, considering all available technical and fundamental data.
Major Takeaways
NuCana PLC, a prominent player in the Healthcare and Biotechnology industry, presents a compelling investment opportunity with its strong product portfolio. Despite reporting an income before tax loss of 32M, the company's net interest income stands at a promising 754K, indicating potential for future profitability.Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Raphi Shpitalnik
The future of medicine is personal. NuCana PLC (NASDAQ: NCNA), a trailblazer in the biotechnology sector, is pushing the boundaries of innovation and proving to be an exciting investment opportunity. With a focus on developing pioneering treatments that transform patients' lives, this health care titan is turning heads in the investment community.
Despite its EBITDA loss of $30.7 million and a net income loss of $27.6 million, NuCana's potential cannot be underestimated. With an enterprise value of $186.3 million, it's clear that investors are recognising the long-term potential of this company. NuCana's commitment to revolutionising healthcare through its cutting-edge biotechnology developments has positioned it as a strong player in the sector.
NuCana's market capitalization stands at $8.2 million, reflecting its current standing in the market. Yet, the analyst estimates suggest a bright future. The lowest estimated target price stands at $4.55, while the highest reaches $5.55. These projections provide a clear signal of potential growth and profitability for those who choose to invest in NuCana's common stock.
As of May 14, 2024, NuCana remains listed and continues to show promise as an investment opportunity. Since its IPO date on September 28, 2017, the company has shown resilience in the face of industry challenges and continues to push the boundaries of biotechnology. While the road to profitability may be long, the potential returns make NuCana PLC a thrilling investment opportunity for stock investors. Currently, NuCana PLC's invested capital is projected to slightly increase, based on recent years' reports. The current year's ratio of intangibles to total assets is expected to grow to 0.08, while the market cap is predicted to decrease to approximately $291.1 million. Despite many traders prioritizing capital preservation over market returns, NuCana PLC could be an exception. In June, we will explore the potential of transforming NuCana PLC into a consistent growth stock. This article will also discuss various factors influencing NuCana PLC's products and services, and how they may impact its investors.The performance of NuCana PLC in the marketplace will significantly impact your decision to invest in its stock. Revenue growth, profitability, competitive positioning, management quality, and industry trends can influence NuCana PLC's stock prices. When investing in NuCana PLC, there are several factors to consider and potential outcomes to expect. As a company performs well, its stock price may increase, allowing investors to benefit from price appreciation. However, NuCana Stock can experience significant price fluctuations due to market conditions, economic factors, industry trends, or company-specific news. This is why investing in stocks such as NuCana PLC carries risks, including the potential for capital loss. Stock prices can decline, and investors may incur losses if they sell shares at a lower price than their initial investment.
Watch out for price decline
Please consider monitoring NuCana PLC on a daily basis if you are holding a position in it. NuCana PLC is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as NuCana PLC stock to be traded above the $1 level to remain listed. If NuCana PLC stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is NuCana PLC's Liquidity
NuCana PLC financial leverage refers to using borrowed capital as a funding source to finance NuCana PLC ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. NuCana PLC financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to NuCana PLC's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of NuCana PLC's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between NuCana PLC's total debt and its cash.
NuCana PLC Gross Profit
NuCana PLC Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing NuCana PLC previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show NuCana PLC Gross Profit growth over the last 10 years. Please check NuCana PLC's gross profit and other fundamental indicators for more details.
Breaking it down a bit more
One of the ways to look at asset utilization of NuCana is to check how much profit was generated for every dollar of assets it reports. NuCana PLC owns a negative utilization of current and long term assets of -0.45 %, losing $0.004516 for each dollar of current and long term assets held by the firm. Unproductive asset utilization conveys that the company is being less effective with each dollar of current and long term assets it owns. Strictly speaking, asset utilization of NuCana PLC shows how inefficient it operates for each dollar spent on its current and long term assets.
"Buy low, sell high" is a classic investment adage that seems to perfectly fit the current situation of NuCana PLC (NCNA). Despite its current low price-to-book ratio of 0.63X, the biotechnology firm holds a robust current ratio of 5.83X, indicating a strong ability to cover its short-term liabilities. Furthermore, Wall Street's target price for NCNA stands at a staggering $125.26, presenting a thrilling potential upside for investors. However, it's worth noting that the company's risk-adjusted performance is currently at -0.07, suggesting some level of risk. Despite this, the firm's solid financial health and the industry's promising growth prospects make NuCana a compelling investment opportunity..
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of NuCana PLC. Please refer to our Terms of Use for any information regarding our disclosure principles.